 |
|
The Association of Cyclosporine With the 1-Year Costs of Cadaver-Donor Kidney Transplants
Jonathan Showstack, MPH;
Patricia Katz, PhD;
William Amend, MD;
Oscar Salvatierra, MD
JAMA. 1990;264(14):1818-1823.
Abstract
| |
Cyclosporine is associated with lower hospitalization costs for transplantation of cadaver kidneys. Whether this cost-lowering effect persists after discharge was assessed for 203 patients who received cadaver kidneys at the University of California, San Francisco, between July 1982 and June 1986. During the transplantation hospitalization period, cyclosporine was associated with significantly better graft survival (88.7% vs 71.0%) and lower (standardized) costs ($37 174 vs $52 983). Following discharge, however, there were no significant differences in graft survival, total charges ($29 716 vs $34 434), the number of readmissions, the total number of days hospitalized, or physician charges, although cyclosporine was associated with higher drug costs ($3885 vs $373). The results suggest that the initial association of cyclosporine with lower costs diminished substantially over time. For grafts that survive beyond several months, there may be little additional cost-reducing benefits of cyclosporine.
(JAMA. 1990;264:1818-1823)
Author Affiliations
From the Institute for Health Policy Studies (Mr Showstack and Dr Katz) and Department of Surgery (Drs Amend and Salvatierra), School of Medicine, University of California, San Francisco.
Footnotes
Reprint requests to Institute for Health Policy Studies, 1326 Third Ave, San Francisco, CA 94143-0936 (Mr Showstack).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Resource Utilization in Liver Transplantation: Effects of Patient Characteristics and Clinical Practice
Showstack et al.
JAMA 1999;281:1381-1386.
ABSTRACT
| FULL TEXT
Elective Cyclosporine Withdrawal After Renal Transplantation: A Meta-analysis
Kasiske et al.
JAMA 1993;269:395-400.
ABSTRACT
|
